Skip to content

Ardelyx ARDX Accrued contract manufacturing expenses

Accrued contract manufacturing expenses at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$17.59M+46.5%
Dow logo
DowDOW
$1.03B-4.4%
Lam Research logo
Lam ResearchLRCX
$2.08B+235%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$9.07M-12.6%
LEC
Lincoln Electric HoldingsLECO
$110.86M-2.6%
Enliven Therapeutics logo
Enliven TherapeuticsELVN
$9.85M-20.7%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:AccruedContractManufacturingExpensesCurrent.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's accrued contract manufacturing expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's accrued contract manufacturing expenses?
Ardelyx (ARDX) reported accrued contract manufacturing expenses of $2.82M in Q4 2025.
What does accrued contract manufacturing expenses mean?
The balance of liabilities owed to third-party manufacturers for the production of drug substances or finished products that have been incurred but not yet paid. This represents the operational cost of maintaining a supply chain through external partners. It is a key indicator of near-term cash outflows required to support commercial or clinical inventory levels.